Form 4: Prelude Therapeutics CMO Reports RSU Vesting

Prelude Therapeutics' President and CMO, Jane Huang, reported the vesting of Restricted Stock Units and subsequent tax-related share disposition.

Summary

• Jane Huang, President and Chief Medical Officer (CMO) of Prelude Therapeutics Inc. (PRLD), reported transactions on October 4, 2025.
• 9,375 Restricted Stock Units (RSUs) vested, converting into common stock.
• 3,355 shares of common stock were disposed of at a price of $1.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Jane Huang directly beneficially owns 86,917 shares of common stock.
• She also beneficially owns 18,750 Restricted Stock Units.
• The RSUs were originally granted on May 2, 2022, with a vesting schedule that commenced with 1/4 of the total shares vesting on April 4, 2023, and 1/16 of the remaining shares vesting quarterly thereafter.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event involving the vesting of Restricted Stock Units, which is a standard practice and reflects continued executive alignment with company performance. There are no unexpected positive or negative operational or financial disclosures.

Positives

• Vesting of 9,375 Restricted Stock Units (RSUs) for President and CMO Jane Huang, reflecting continued compensation and alignment with shareholder interests through equity ownership.

Negatives

• Disposition of 3,355 shares of common stock at $1.47 per share to cover tax withholding obligations, which reduces the direct share ownership of the executive.

Future Outlook

The remaining Restricted Stock Units (RSUs) will continue to vest quarterly, subject to Jane Huang's continued service to the Issuer, as per the established vesting schedule.

Industry Context

This Form 4 filing details a routine executive compensation event (RSU vesting and tax withholding) for a key executive. It does not provide information directly related to broader industry trends, competitive positioning, or the company's operational performance within the biotech sector.

Related Party Transactions

• Vesting of Restricted Stock Units (RSUs) for President and CMO Jane Huang, and subsequent disposition of shares to cover tax obligations, representing a standard executive compensation transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The vesting of RSUs is a standard component of executive compensation, aligning executive interests with shareholder value, though it involves a minor, pre-planned dilution.
• Employees: Reflects the company's ongoing executive compensation practices, which typically include equity awards to incentivize long-term performance and retention.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest quarterly as per the established schedule, contingent on Jane Huang's continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting and tax withholding) for a key executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and does not indicate any material positive or negative developments for the company's stock price.

Keywords

Prelude Therapeutics, PRLD, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Jane Huang